Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Arrhythmias

  Free Subscription


Articles published in Eur Heart J

Retrieve available abstracts of 143 articles:
HTML format
Text format



Single Articles


    October 2019
  1. JAMES CA, Calkins H
    Arrhythmogenic right ventricular cardiomyopathy: evidence for progression increases.
    Eur Heart J. 2019 Oct 16. pii: 5588521. doi: 10.1093.
    PubMed     Text format    


  2. RICHTER S, Di Biase L, Hindricks G
    Atrial fibrillation ablation in heart failure: it's not all about Starling my darling.
    Eur Heart J. 2019 Oct 3. pii: 5580540. doi: 10.1093.
    PubMed     Text format    


    September 2019
  3. WIJTVLIET EPJP, Tieleman RG, van Gelder IC, Pluymaekers NAHA, et al
    Nurse-led vs. usual-care for atrial fibrillation.
    Eur Heart J. 2019 Sep 23. pii: 5572602. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. LUSCHER TF
    Risks and management of cardioversion and catheter ablation in atrial fibrillation.
    Eur Heart J. 2019;40:2999-3002.
    PubMed     Text format    


  5. GUHA A, Dey AK, Jneid H, Ibarz JP, et al
    Atrial Fibrillation in the Era of Emerging Cancer Therapies.
    Eur Heart J. 2019;40:3007-3010.
    PubMed     Text format    


  6. LIP GYH, Guo Y, Lotufo P, Surenthirakumaran R, et al
    The National Institute for Health Research (NIHR) Global Health Research Group on Atrial Fibrillation management.
    Eur Heart J. 2019;40:3005-3007.
    PubMed     Text format    


  7. SULZGRUBER P, Wassmann S, Semb AG, Doehner W, et al
    Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.
    Eur Heart J. 2019;40:3010-3012.
    PubMed     Text format    


  8. VON OERTZEN TJ, Trinka E, Bornstein NM
    Levetiracetam and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and epilepsy: a reasonable combination.
    Eur Heart J. 2019 Sep 20. pii: 5572225. doi: 10.1093.
    PubMed     Text format    


  9. POTPARA T, Steffel J
    Strategies in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants (NOACs) and co-medications with possible drug-drug interaction.
    Eur Heart J. 2019 Sep 20. pii: 5572224. doi: 10.1093.
    PubMed     Text format    


    August 2019
  10. KLEIN HU
    Elective DC cardioversion of atrial fibrillation: did we use the right procedure?
    Eur Heart J. 2019 Aug 31. pii: 5554427. doi: 10.1093.
    PubMed     Text format    


  11. SCHMIDT AS, Lauridsen KG, Torp P, Bach LF, et al
    Maximum-fixed energy shocks for cardioverting atrial fibrillation.
    Eur Heart J. 2019 Aug 31. pii: 5552545. doi: 10.1093.
    PubMed     Text format     Abstract available



  12. Corrigendum to: Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
    Eur Heart J. 2019 Aug 29. pii: 5556355. doi: 10.1093.
    PubMed     Text format    


  13. VERHEUGT FWA
    Cardioversion as bystander in atrial fibrillation-related thrombo-embolism.
    Eur Heart J. 2019 Aug 7. pii: 5544748. doi: 10.1093.
    PubMed     Text format    


  14. MCINTYRE WF, Connolly SJ, Wang J, Masiero S, et al
    Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials.
    Eur Heart J. 2019 Aug 4. pii: 5543556. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2019
  15. FREY SM, Sticherling C, Mueller C
    Comment to: Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar.
    Eur Heart J. 2019 Jul 30. pii: 5541022. doi: 10.1093.
    PubMed     Text format    


  16. GUTMAN SJ, Taylor AJ
    Reply to letter by Frey et al. regarding the article: Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar.
    Eur Heart J. 2019 Jul 30. pii: 5541020. doi: 10.1093.
    PubMed     Text format    


  17. KUHNE M, Krisai P, Conen D, Osswald S, et al
    The heart-brain connection: further establishing the relationship between atrial fibrillation and dementia?
    Eur Heart J. 2019;40:2324-2326.
    PubMed     Text format    


  18. NAZIF TM, Chen S, George I, Dizon JM, et al
    New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial.
    Eur Heart J. 2019;40:2218-2227.
    PubMed     Text format     Abstract available


  19. KILLU AM, Gersh BJ
    Response to: Risk stratification for stroke in atrial fibrillation: incorporating neurologists in the comprehensive management.
    Eur Heart J. 2019 Jul 13. pii: 5532107. doi: 10.1093.
    PubMed     Text format    


  20. LI HF, Liang B, Li HY
    Risk stratification for stroke in atrial fibrillation: incorporating neurologists in the comprehensive management.
    Eur Heart J. 2019 Jul 13. pii: 5532108. doi: 10.1093.
    PubMed     Text format    


  21. CHEN S, Purerfellner H, Meyer C, Acou WJ, et al
    Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data.
    Eur Heart J. 2019 Jul 11. pii: 5531275. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2019
  22. CLELAND JGF, Hindricks G, Petrie M
    The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization.
    Eur Heart J. 2019 Jun 30. pii: 5525356. doi: 10.1093.
    PubMed     Text format    


  23. KOTECHA D, Castella M
    Is it time to treat post-operative atrial fibrillation just like regular atrial fibrillation?
    Eur Heart J. 2019 Jun 25. pii: 5523037. doi: 10.1093.
    PubMed     Text format    


  24. CONEN D, Alonso-Coello P, Douketis J, Chan MTV, et al
    Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery.
    Eur Heart J. 2019 Jun 25. pii: 5523034. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. PIAZZA G, Hurwitz S, Galvin CE, Harrigan L, et al
    Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT).
    Eur Heart J. 2019 Jun 22. pii: 5521151. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. KIM D, Yang PS, Yu HT, Kim TH, et al
    Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort.
    Eur Heart J. 2019 Jun 18. pii: 5520105. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. DEMEESTERE J, Lemmens R
    Anticoagulation in low-risk patients with atrial fibrillation: beyond prevention of ischaemic stroke.
    Eur Heart J. 2019 Jun 18. pii: 5519990. doi: 10.1093.
    PubMed     Text format    


  28. FENG T, Vegard M, Strand LB, Laugsand LE, et al
    Weight and weight change and risk of atrial fibrillation: the HUNT study.
    Eur Heart J. 2019 Jun 17. pii: 5519674. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. SCHWARTZ PJ, Woosley RL, Crotti L
    When prescribing drugs, do medical doctors and healthcare professionals realize that their patient has the long QT syndrome?
    Eur Heart J. 2019 Jun 14. pii: 5519086. doi: 10.1093.
    PubMed     Text format    


  30. SHAH DC
    Longitudinal, long-term evaluation of new-onset atrial fibrillation: the interplay of blood pressure burden over time and gender.
    Eur Heart J. 2019 Jun 3. pii: 5510138. doi: 10.1093.
    PubMed     Text format    


    May 2019
  31. VAN DER WERF C, Lieve KV, Bos JM, Lane CM, et al
    Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest.
    Eur Heart J. 2019 May 30. pii: 5506735. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. FRIBERG L, Andersson T, Rosenqvist M
    Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation.
    Eur Heart J. 2019 May 16. pii: 5490291. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. PACKER M
    Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation.
    Eur Heart J. 2019 May 12. pii: 5488510. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. WEEKE PE, Kellemann JS, Jespersen CB, Theilade J, et al
    Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality.
    Eur Heart J. 2019 May 11. pii: 5488147. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. SHARASHOVA E, Wilsgaard T, Ball J, Morseth B, et al
    Long-term blood pressure trajectories and incident atrial fibrillation in women and men: the Tromso Study.
    Eur Heart J. 2019 May 3. pii: 5485289. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2019
  36. VON HAEHLING S, Doehner W, Anker SD
    The evolving obesity paradigm story: from heart failure to atrial fibrillation.
    Eur Heart J. 2019 Apr 21. pii: 5476266. doi: 10.1093.
    PubMed     Text format    


  37. MCKENNA WJ, Asaad NA, Jacoby DL
    Prediction of ventricular arrhythmia and sudden death in arrhythmogenic right ventricular cardiomyopathy.
    Eur Heart J. 2019 Apr 11. pii: 5448878. doi: 10.1093.
    PubMed     Text format    


  38. HOHNLOSER SH, Camm J, Cappato R, Diener HC, et al
    Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
    Eur Heart J. 2019 Apr 11. pii: 5446017. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. SCHULZ SM, Ritter O, Zniva R, Nordbeck P, et al
    Efficacy of a web-based intervention for improving psychosocial well-being in patients with implantable cardioverter-defibrillators: the randomized controlled ICD-FORUM trial.
    Eur Heart J. 2019 Apr 8. pii: 5431178. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. MEHRAN R, Kalkman DN, Angiolillo DJ
    Atrial fibrillation, with ACS and PCI: walking a tightrope.
    Eur Heart J. 2019 Apr 8. pii: 5431179. doi: 10.1093.
    PubMed     Text format    


  41. BONDE AN, Blanche P, Staerk L, Gerds TA, et al
    Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study.
    Eur Heart J. 2019 Apr 1. pii: 5424120. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2019
  42. CHEUNG JW, Cheng EP, Wu X, Yeo I, et al
    Sex-based differences in outcomes, 30-day readmissions, and costs following catheter ablation of atrial fibrillation: the United States Nationwide Readmissions Database 2010-14.
    Eur Heart J. 2019 Mar 29. pii: 5422981. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. SINGH JA, Cleveland JD
    Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data.
    Eur Heart J. 2019 Mar 28. pii: 5421316. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. CADRIN-TOURIGNY J, Bosman LP, Nozza A, Wang W, et al
    A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy.
    Eur Heart J. 2019 Mar 27. pii: 5419784. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. NOSEWORTHY PA, Gersh BJ, Kent DM, Piccini JP, et al
    Atrial fibrillation ablation in practice: assessing CABANA generalizability.
    Eur Heart J. 2019 Mar 15. pii: 5381200. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. CAMM AJ
    Left atrial ablation for management of atrial fibrillation: CABANA vs. real-world data. Apples and oranges?
    Eur Heart J. 2019 Mar 15. pii: 5381199. doi: 10.1093.
    PubMed     Text format    


  47. CONEN D
    Alcohol and Atrial Fibrillation.
    Eur Heart J. 2019;40:796-797.
    PubMed     Text format    


    February 2019
  48. OZKARTAL T, Auricchio A, Conte G
    Ajmaline infusion during automated screening in Brugada syndrome and spontaneous Type 1 electrocardiogram unmasks non-suitability for subcutaneous implantable cardioverter-defibrillator.
    Eur Heart J. 2019 Feb 21. pii: 5359472. doi: 10.1093.
    PubMed     Text format    


  49. OLDGREN J, Steg PG, Hohnloser SH, Lip GYH, et al
    Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
    Eur Heart J. 2019 Feb 21. pii: 5359476. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. VAN DEN BERG MP, Mulder BA, Klaassen SHC, Maass AH, et al
    Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.
    Eur Heart J. 2019 Feb 8. pii: 5310346. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. SCHWARTZ PJ, Gnecchi M, Dagradi F, Castelletti S, et al
    From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2.
    Eur Heart J. 2019 Feb 6. pii: 5307938. doi: 10.1093.
    PubMed     Text format     Abstract available


  52. TRENKWALDER T, Schunkert H
    Risk of atrial fibrillation in big people under the magnifying glass of G. J. Mendel.
    Eur Heart J. 2019 Feb 5. pii: 5306113. doi: 10.1093.
    PubMed     Text format    


  53. TIKKANEN E, Gustafsson S, Knowles JW, Perez M, et al
    Body composition and atrial fibrillation: a Mendelian randomization study.
    Eur Heart J. 2019 Feb 5. pii: 5306116. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2019
  54. BUNCH JT, Woller SC
    Saving the brain from catheter ablation of atrial fibrillation: the role of pre- and peri-procedural anticoagulation.
    Eur Heart J. 2019 Jan 31. pii: 5305045. doi: 10.1093.
    PubMed     Text format    


  55. VERKERK AO, Remme CA
    Down the rabbit hole: deciphering the short QT syndrome.
    Eur Heart J. 2019 Jan 27. pii: 5303207. doi: 10.1093.
    PubMed     Text format    


  56. GOLDHABER SZ, Piazza G
    Fine-tuning the decision to initiate anticoagulation in atrial fibrillation by accounting for age and cardiovascular comorbidities.
    Eur Heart J. 2019 Jan 25. pii: 5301477. doi: 10.1093.
    PubMed     Text format    


  57. KHAN AA, Lip GYH
    Non-vitamin K antagonist oral anticoagulants beyond atrial fibrillation: what did we learn from COMPASS and COMMANDER-HF?
    Eur Heart J. 2019 Jan 21. pii: 5298544. doi: 10.1093.
    PubMed     Text format    


  58. BORIANI G, Ruff CT, Kuder JF, Shi M, et al
    Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
    Eur Heart J. 2019 Jan 8. pii: 5280832. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. CHUA W, Purmah Y, Cardoso VR, Gkoutos GV, et al
    Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation.
    Eur Heart J. 2019 Jan 7. pii: 5270657. doi: 10.1093.
    PubMed     Text format     Abstract available


  60. KIM TH, Yang PS, Yu HT, Jang E, et al
    Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population.
    Eur Heart J. 2019 Jan 4. pii: 5273478. doi: 10.1093.
    PubMed     Text format     Abstract available


  61. CHAO TF, Lip GYH, Lin YJ, Chang SL, et al
    Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities.
    Eur Heart J. 2019 Jan 2. pii: 5272355. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2018
  62. YU HT, Shim J, Park J, Kim TH, et al
    When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
    Eur Heart J. 2018 Dec 27. pii: 5263768. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. WANG KL, Lopes RD, Patel MR, Buller HR, et al
    Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
    Eur Heart J. 2018 Dec 22. pii: 5255630. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. CHAO TF, Chen SA, Ruff CT, Hamershock RA, et al
    Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.
    Eur Heart J. 2018 Dec 22. pii: 5258031. doi: 10.1093.
    PubMed     Text format     Abstract available


  65. RICHTER S, Di Biase L, Hindricks G
    Atrial fibrillation ablation in heart failure.
    Eur Heart J. 2018 Dec 14. pii: 5248225. doi: 10.1093.
    PubMed     Text format     Abstract available


  66. KILLU AM, Granger CB, Gersh BJ
    Risk stratification for stroke in atrial fibrillation: a critique.
    Eur Heart J. 2018 Dec 1. pii: 5224504. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2018
  67. STEFFEL J, Potpara TS
    Challenges in clinical decision-making on concomitant drug therapies in patients with atrial fibrillation taking oral anticoagulants.
    Eur Heart J. 2018 Nov 29. pii: 5219661. doi: 10.1093.
    PubMed     Text format    


  68. ODENING KE, Bodi I, Franke G, Rieke R, et al
    Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility.
    Eur Heart J. 2018 Nov 28. pii: 5212713. doi: 10.1093.
    PubMed     Text format     Abstract available


  69. LUSCHER TF
    Dangerous encounters: triggers of fatal ventricular arrhythmias and safety of interventional treatment strategies.
    Eur Heart J. 2018;39:3909-3912.
    PubMed     Text format    


  70. SIONTIS KC, Yao X, Noseworthy PA
    Atrial fibrillation in heart failure syndromes: does it matter more in some than in others?
    Eur Heart J. 2018 Nov 20. pii: 5193438. doi: 10.1093.
    PubMed     Text format    


  71. NISHIMURA M, Maisel AS
    Biomarkers: a window into the pathophysiology of atrial fibrillation in heart failure with reduced vs. preserved ejection fraction.
    Eur Heart J. 2018;39:3876-3878.
    PubMed     Text format    


  72. GOLWALA H, Cannon CP, Bhatt DL
    Reply to: Dual vs. triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Eur Heart J. 2018 Nov 5. pii: 5161202. doi: 10.1093.
    PubMed     Text format    


  73. GRAGNANO F, Calabro P, Valgimigli M
    Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?
    Eur Heart J. 2018 Nov 5. pii: 5161206. doi: 10.1093.
    PubMed     Text format    


    October 2018
  74. BOERSMA LVA
    Biventricular pacing after AV-node ablation for atrial fibrillation with heart failure: something old and something new, future standard, or just for the few?
    Eur Heart J. 2018 Oct 25. pii: 5145027. doi: 10.1093.
    PubMed     Text format    


  75. JOHN RM, Michaud GF, Stevenson WG
    Atrial fibrillation hospitalization, mortality, and therapy.
    Eur Heart J. 2018 Oct 16. pii: 5133619. doi: 10.1093.
    PubMed     Text format    


  76. ZAFRIR B, Lund LH, Laroche C, Ruschitzka F, et al
    Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.
    Eur Heart J. 2018 Oct 15. pii: 5133012. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2018
  77. CALKINS H
    A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy: is this too good to be true?
    Eur Heart J. 2018 Sep 17. pii: 5098639. doi: 10.1093.
    PubMed     Text format    


  78. CHATTERJEE D, Fatah M, Akdis D, Spears DA, et al
    An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis.
    Eur Heart J. 2018 Sep 17. pii: 5098642. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  79. BRIGNOLE M, Pokushalov E, Pentimalli F, Palmisano P, et al
    A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS.
    Eur Heart J. 2018 Aug 26. pii: 5078460. doi: 10.1093.
    PubMed     Text format     Abstract available


  80. SANTEMA BT, Kloosterman M, Van Gelder IC, Mordi I, et al
    Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.
    Eur Heart J. 2018 Aug 22. pii: 5077588. doi: 10.1093.
    PubMed     Text format     Abstract available


  81. GUTMAN SJ, Costello BT, Papapostolou S, Voskoboinik A, et al
    Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar.
    Eur Heart J. 2018 Aug 10. pii: 5070406. doi: 10.1093.
    PubMed     Text format     Abstract available


  82. FREEDMAN B
    Major progress in anticoagulant uptake for atrial fibrillation at last: does it translate into stroke prevention?
    Eur Heart J. 2018 Aug 10. pii: 5070412. doi: 10.1093.
    PubMed     Text format    


  83. POLOVINA M, Hindricks G, Maggioni A, Piepoli M, et al
    Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation.
    Eur Heart J. 2018 Aug 7. pii: 5067645. doi: 10.1093.
    PubMed     Text format     Abstract available


  84. STEINBECK G, Sinner MF, Lutz M, Muller-Nurasyid M, et al
    Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014.
    Eur Heart J. 2018 Aug 1. pii: 5063863. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  85. PATHAK RK, Sanders P, Deo R
    Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy.
    Eur Heart J. 2018 Jul 17. pii: 5055243. doi: 10.1093.
    PubMed     Text format     Abstract available


  86. COWAN JC, Wu J, Hall M, Orlowski A, et al
    A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation.
    Eur Heart J. 2018 Jul 5. pii: 5049393. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  87. MAROTT JL, Skielboe AK, Dixen U, Friberg JB, et al
    Increasing population height and risk of incident atrial fibrillation: the Copenhagen City Heart Study.
    Eur Heart J. 2018 Jun 28. pii: 5046683. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  88. FRIEDMAN DJ, Granger CB
    Uninterrupted apixaban for atrial fibrillation ablation is a reasonable alternative, but what is the significance of silent cerebral infarctions?
    Eur Heart J. 2018 May 19. pii: 4999868. doi: 10.1093.
    PubMed     Text format    


    April 2018
  89. FANAROFF AC, Steffel J, Alexander JH, Lip GYH, et al
    Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe.
    Eur Heart J. 2018 Apr 23. pii: 4982606. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. LUSCHER TF
    Atrial fibrillation and arrhythmias: novel risk assessment, proper anticoagulation, and ablation.
    Eur Heart J. 2018;39:1317-1321.
    PubMed     Text format    


  91. CONEN D
    Epidemiology of atrial fibrillation.
    Eur Heart J. 2018;39:1323-1324.
    PubMed     Text format    


  92. GOLWALA HB, Cannon CP, Steg PG, Doros G, et al
    Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.
    Eur Heart J. 2018 Apr 13. pii: 4970508. doi: 10.1093.
    PubMed     Text format     Abstract available


  93. EZEKOWITZ MD, Pollack CV Jr, Halperin JL, England RD, et al
    Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
    Eur Heart J. 2018 Apr 6. pii: 4963487. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  94. POKORNEY SD, Daubert JP
    Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug?
    Eur Heart J. 2018 Mar 27. pii: 4955289. doi: 10.1093.
    PubMed     Text format    


  95. KIRCHHOF P, Haeusler KG, Blank B, De Bono J, et al
    Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.
    Eur Heart J. 2018 Mar 20. pii: 4943979. doi: 10.1093.
    PubMed     Text format     Abstract available


  96. STEFFEL J, Verhamme P, Potpara TS, Albaladejo P, et al
    The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Eur Heart J. 2018 Mar 17. pii: 4942493. doi: 10.1093.
    PubMed     Text format     Abstract available


  97. WALDMANN V, Bougouin W, Karam N, Dumas F, et al
    Characteristics and clinical assessment of unexplained sudden cardiac arrest in the real-world setting: focus on idiopathic ventricular fibrillation.
    Eur Heart J. 2018 Mar 16. pii: 4939309. doi: 10.1093.
    PubMed     Text format     Abstract available


  98. HASEGAWA K, Kaseno K, Aiki T, Tada H, et al
    Left atrial sarcoidosis as a substrate for peri-mitral atrial flutter: an unusual, underlying atrial disease.
    Eur Heart J. 2018 Mar 15. pii: 4938722. doi: 10.1093.
    PubMed     Text format    


    February 2018
  99. LANCELLOTTI P, Galderisi M
    Prediction of ischaemic stroke in non-valvular atrial fibrillation if advanced echocardiography plays the game.
    Eur Heart J. 2018 Feb 9. pii: 4847811. doi: 10.1093.
    PubMed     Text format    


  100. RIENSTRA M, Hobbelt AH, Alings M, Tijssen JGP, et al
    Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.
    Eur Heart J. 2018 Feb 1. pii: 4786620. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  101. MAHAJAN R, Perera T, Elliott AD, Twomey DJ, et al
    Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis.
    Eur Heart J. 2018 Jan 10. pii: 4797540. doi: 10.1093.
    PubMed     Text format     Abstract available


  102. HEALEY JS
    The winding path towards rationale anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation.
    Eur Heart J. 2018 Jan 9. pii: 4796907. doi: 10.1093.
    PubMed     Text format    


  103. LIP GYH, Lane DA, Potpara TS
    Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation.
    Eur Heart J. 2018 Jan 6. pii: 4791955. doi: 10.1093.
    PubMed     Text format    


  104. DESTEGHE L, Vijgen J, Koopman P, Dilling-Boer D, et al
    Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation.
    Eur Heart J. 2018 Jan 2. pii: 4782504. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  105. LEUNG M, van Rosendael PJ, Abou R, Ajmone Marsan N, et al
    Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry.
    Eur Heart J. 2017 Dec 28. pii: 4781364. doi: 10.1093.
    PubMed     Text format     Abstract available


  106. VERHEUGT FWA, Gao H, Al Mahmeed W, Ambrosio G, et al
    Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry.
    Eur Heart J. 2017 Dec 20. pii: 4769347. doi: 10.1093.
    PubMed     Text format     Abstract available


  107. POKORNEY SD, Granger CB
    Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation.
    Eur Heart J. 2017 Dec 13. pii: 4735276. doi: 10.1093.
    PubMed     Text format    


  108. DUYTSCHAEVER M, Demolder A, Phlips T, Sarkozy A, et al
    PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial.
    Eur Heart J. 2017 Dec 2. pii: 4683714. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  109. SPOSATO LA, Lopes RD
    Oral anticoagulation: a step toward solving the puzzle of dementia related to atrial fibrillation?
    Eur Heart J. 2017 Nov 27. pii: 4665696. doi: 10.1093.
    PubMed     Text format    


  110. PICCINI JP, Kirchhof P
    Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?
    Eur Heart J. 2017 Nov 22. pii: 4652880. doi: 10.1093.
    PubMed     Text format    


  111. STAERK L, Fosbol EL, Lamberts M, Bonde AN, et al
    Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study.
    Eur Heart J. 2017 Nov 18. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  112. FRIBERG L, Rosenqvist M
    Less dementia with oral anticoagulation in atrial fibrillation.
    Eur Heart J. 2017 Oct 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  113. LIP GYH, Lane DA, Sarwar S
    Streamlining primary and secondary care management pathways for stroke prevention in atrial fibrillation.
    Eur Heart J. 2017;38:2980-2982.
    PubMed     Text format    


  114. HIJAZI Z, Oldgren J, Lindback J, Alexander JH, et al
    A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.
    Eur Heart J. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  115. DELISLE BP, January CT
    Advancing precision medicine for the treatment of long-QT syndrome type 2: shedding light on lumacaftor.
    Eur Heart J. 2017 Oct 11. doi: 10.1093.
    PubMed     Text format    


    September 2017
  116. KOTECHA D, Kirchhof P
    ESC Apps for Atrial Fibrillation.
    Eur Heart J. 2017;38:2643-2645.
    PubMed     Text format    


  117. LUSCHER TF
    Risk factors and consequences of atrial fibrillation: genetics, blood pressure, working hours, and cognitive decline.
    Eur Heart J. 2017;38:2573-2575.
    PubMed     Text format    


  118. KIRCHHOF P, Sanders P
    My atrial fibrillation is not your atrial fibrillation.
    Eur Heart J. 2017;38:2608-2611.
    PubMed     Text format    


  119. MAHMOODI BK, Boersma LV
    Do long working hours predispose to atrial fibrillation?
    Eur Heart J. 2017;38:2629-2631.
    PubMed     Text format    


  120. KIVIMAKI M, Nyberg ST, Batty GD, Kawachi I, et al
    Long working hours as a risk factor for atrial fibrillation: a multi-cohort study.
    Eur Heart J. 2017;38:2621-2628.
    PubMed     Text format     Abstract available


    August 2017
  121. PALLISGAARD JL, Gislason GH, Hansen J, Johannessen A, et al
    Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study.
    Eur Heart J. 2017 Aug 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  122. KIRCHHOF P, Schroeder S
    NOACs in Atrial Fibrillation.
    Eur Heart J. 2017;38:2382-2385.
    PubMed     Text format    


    July 2017
  123. MEHTA A, Ramachandra CJA, Singh P, Chitre A, et al
    Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model.
    Eur Heart J. 2017 Jul 21. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2017
  124. LEE SS, Ae Kong K, Kim D, Lim YM, et al
    Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea.
    Eur Heart J. 2017 Jun 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  125. HUANG H, Darbar D
    Genetic heterogeneity of atrial fibrillation susceptibility loci across racial or ethnic groups.
    Eur Heart J. 2017 Jun 14. doi: 10.1093.
    PubMed     Text format    


  126. DIENER HC
    Does atrial fibrillation lead to cognitive decline and dementia?
    Eur Heart J. 2017 Jun 14. doi: 10.1093.
    PubMed     Text format    


    May 2017
  127. LUSCHER TF
    Gender issues in arrhythmias: from atrial fibrillation to CRT and arrhythmogenic ventricular cardiomyopathy.
    Eur Heart J. 2017;38:1443-1446.
    PubMed     Text format    


    April 2017
  128. SINGH-MANOUX A, Fayosse A, Sabia S, Canonico M, et al
    Atrial fibrillation as a risk factor for cognitive decline and dementia.
    Eur Heart J. 2017 Apr 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  129. LEE JY, Kim TH, Yang PS, Lim HE, et al
    Korean atrial fibrillation network genome-wide association study for early-onset atrial fibrillation identifies novel susceptibility loci.
    Eur Heart J. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  130. RAHIMI K
    Subclinical atrial fibrillation in need of more assertive evidence.
    Eur Heart J. 2017 Mar 31. doi: 10.1093.
    PubMed     Text format    


  131. SETO AH, Abbott NJ, Makkar RR, Salazar MA, et al
    Sustained left ventricular outflow tract ventricular tachycardia following transcatheter aortic valve replacement.
    Eur Heart J. 2017 Mar 28. doi: 10.1093.
    PubMed     Text format    



  132. Corrigendum to: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS'.
    Eur Heart J. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format    


  133. CAMM AJ, Savelieva I
    Female gender as a risk factor for stroke associated with atrial fibrillation.
    Eur Heart J. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format    


  134. LUSCHER TF
    Atrial fibrillation and thrombo- embolism: anticoagulants or devices?
    Eur Heart J. 2017;38:839-842.
    PubMed     Text format    


  135. ABDUL-RAHIM AH, Perez AC, MacIsaac RL, Jhund PS, et al
    Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
    Eur Heart J. 2017;38:742-750.
    PubMed     Text format     Abstract available


  136. BAX JJ, Delgado V, Sogaard P, Singh JP, et al
    Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.
    Eur Heart J. 2017;38:720-726.
    PubMed     Text format     Abstract available


  137. VAN GELDER IC, Healey JS, Crijns HJ, Wang J, et al
    Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.
    Eur Heart J. 2017 Mar 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  138. SHUN-SHIN MJ, Zheng SL, Cole GD, Howard JP, et al
    Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials.
    Eur Heart J. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  139. AKDIS D, Saguner AM, Shah K, Wei C, et al
    Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome.
    Eur Heart J. 2017 Feb 18. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2017
  140. REINER MF, Breitenstein A, Holy EW, Glanzmann M, et al
    Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium.
    Eur Heart J. 2017 Jan 8. pii: ehw578. doi: 10.1093.
    PubMed     Text format     Abstract available


  141. BAVENDIEK U, Aguirre Davila L, Koch A, Bauersachs J, et al
    Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.
    Eur Heart J. 2017 Jan 8. pii: ehw577. doi: 10.1093.
    PubMed     Text format    


  142. GAL P, Marrouche NF
    Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome.
    Eur Heart J. 2017;38:14-19.
    PubMed     Text format     Abstract available


    September 2016
  143. PICCINI JP, Sievert H, Patel MR
    Left atrial appendage occlusion: rationale, evidence, devices, and patient selection.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: